Wolverine Trading
TVTX icon

Wolverine Trading’s Travere Therapeutics TVTX Stock Holding History

Wolverine Trading’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-10,632
Closed -$235K – 5330
2018
Q4 		$237K Buy
+10,632
New +$264K ﹤0.01% 3498
2016
Q3 		– Sell
-21,955
Closed -$418K – 5118
2016
Q2 		$394K Buy
+21,955
New +$355K ﹤0.01% 2477

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Wolverine Trading's TVTX Position: Q1 2019 in Review

Wolverine Trading sold out of Travere Therapeutics (TVTX) in Q1 2019, closing a stake of 10,632 shares — an estimated $235K sold.

Wolverine Trading first reported a position in TVTX in Q2 2016 and held it in 2 quarters. The position peaked at $394K in Q2 2016. 131 funds tracked by Wall St. Rank hold TVTX as of Q1 2019.

  • Wolverine Trading reported no remaining Travere Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Wolverine Trading sold 10,632 Travere Therapeutics shares in Q1 2019, an estimated $235K.
  • Wolverine Trading first reported a position in Travere Therapeutics in Q2 2016 and held it in 2 quarters.
  • Wolverine Trading's Travere Therapeutics position peaked at $394K in Q2 2016.
  • 131 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2019.

Based on Wolverine Trading's 13F filing for Q1 2019, filed 15 May 2019.